Inpharma 1573 - 3 Feb 2007

Other EU regulatory newsThe CHMP of the EMEA has issued a positive opinion

recommending the approval of sodium oxybate[Xyrem; UCB] in the treatment of narcolepsy withcataplexy in adults in the EU.1

Merck & Co’s sitagliptin [Januvia] has received apositive opinion from the CHMP for use in the treatmentof patients with type 2 diabetes mellitus.2

1. UCB. European Medicines Agency Adopts Positive Opinion RecommendingApproval of Xyrem(R) for the Treatment of Narcolepsy with Cataplexy in AdultPatients. Media Release : 25 Jan 2007. Available from: URL: http://www.ucb-group.com.

2. Merck & Co Inc. JANUVIA™, First in New Class of Oral Treatments Knownas DPP-4 Inhibitors, Recommended for Approval for the Treatment of Type 2Diabetes in the European Union. Media Release : 26 Jan 2007. Available from:URL: http://www.merck.com.

801069408

1

Inpharma 3 Feb 2007 No. 15731173-8324/10/1573-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved